After an 8% fall in first quarter US sales over the previous quarter led by the impact of COVID-19 and the seasonal drop in sales of oseltamivir, Zydus Cadila expects “mid-to-high” single digit growth in its biggest market during financial year 2021. Prospects for India sales, which also dipped during Q1, are seen improving too.
As one of the main contributors to US revenue, Asacol -HD (mesalamine) delayed release tablets for treatment of mild to...